Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
Source: finance.yahoo.com
Related posts:
‘They promise so much.’ Are those Medicare Advantage TV ads for real?
Mark Cuban, Mavericks in hot water over Voyager 'Ponzi scheme'
Meet the Boring Stock That's Absolutely Crushing Amazon
Tesla Will Probably Beat Earnings Estimates. Why the Stock Might Not Move.
Tesla Stock Today: Cybertruck Crash, Reading the Chart, and a Very Good Year